QuidelOrtho Corp (QDEL) · Sep 23, 2026 · Other events

QuidelOrtho secures covenant relief as weak demand strains deleveraging

Covenant relief — Leverage cap relaxed to 5.50x and interest-coverage floor cut to 2.25x through July 2028

QuidelOrtho loosens debt tests through 2029, gaining runway while underscoring pressure from weaker demand and elevated leverage.

QuidelOrtho is trying to rebuild cash flow and reduce debt while dealing with weaker respiratory demand and a reset of its 2026 outlook; management had cut 2026 revenue guidance to $2.52–$2.60 billion from $2.70–$2.75 billion and withdrawn free-cash-flow guidance.

The amendment gives the company meaningful breathing room. It resets the financial covenants through September 30, 2029. 〔0〕

Credit termAmendment termsTiming
Maximum leverage ratio5.50xOn or before July 2, 2028
Minimum interest coverage2.25xOn or before July 2, 2028
Maximum leverage ratio5.00xOctober 1 or December 31, 2028
Minimum interest coverage2.50xOctober 1 or December 31, 2028
Maximum leverage ratio4.50xApril 1 or July 1, 2029
Minimum interest coverage2.75xApril 1 or July 1, 2029
Maximum leverage ratio4.25xSeptember 30, 2029 onward
Minimum interest coverage3.00xSeptember 30, 2029 onward

The relief is also a warning about the starting point. Compared with the prior agreement’s 4.50x leverage cap and 3.00x interest-coverage floor, the temporary 5.50x and 2.25x thresholds are materially looser. That does not change the debt balance, but it acknowledges that weaker earnings or cash generation could otherwise make compliance difficult. The company’s existing financing totals $3.4 billion across term loans and revolver capacity, including a $1.15 billion Term Loan A, $100 million delayed-draw facility, $1.45 billion Term Loan B and $700 million revolver.

This is runway, not a cure. Interest rates on the Term Loan A and revolver remain tied to leverage and can reach 3.00% over Term SOFR plus the applicable base spread, while the Term Loan B economics are unchanged. 〔1〕 The company also adds restrictions during the relief period, so flexibility is being purchased with tighter operating guardrails rather than through debt reduction.

Bottom line: The amendment reduces near-term covenant risk and gives QuidelOrtho time to repair cash flow, but it also confirms that leverage has become a central constraint. It matters because the company now has more runway, not because its underlying debt problem has been solved.

What to watch next

Q3 compliance certificate, expected after September 28, 2026

Original filing on SEC EDGAR

More QuidelOrtho Corp news

QuidelOrtho secures covenant relief as weak demand strains deleveraging | QDEL Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.